Dec 01, 2017
FDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan's Deep Expertise in Developing Complex Products
Nov 13, 2017
New RE-VERSE AD(TM) Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery
Nov 13, 2017
New Study Consistent with Trial Results for Dabigatran and Warfarin in Atrial Fibrillation
Nov 10, 2017
Boehringer Ingelheim Presents New Data for Pradaxa® and its Specific Reversal Agent Idarucizumab (Praxbind®) at AHA Scientific Sessions 2017
Nov 03, 2017
US Anticoagulation Therapy Market Worth 27.83 Billion USD by 2022
Oct 26, 2017
CeloNova's COBRA PzF NanoCoated Coronary Stent (NCS) Being Studied with 14-day DAPT in High Bleeding Risk Patients
Oct 17, 2017
Antithrombin Market to Attract a Revenue of US $704.5 Million by 2025 Globally: Transparency Market Research
Oct 05, 2017
NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
Aug 27, 2017
RE-DUAL PCI(TM) Results Offer Favorable New Safety Data on Pradaxa®
Aug 22, 2017
Landmark GARFIELD-AF Data to be Presented at ESC 2017 Congress Will Feature 1-year Outcomes on 52,000 Prospective Patients and the First Insights From the Registry on Health Economics in Atrial Fibrillation (AF)
Aug 16, 2017
Global Acute Ischemic Stroke Therapeutics Market to Grow at a CAGR of 2.1% by 2021: Driven by the Increasing Adoption of NOACs
Jun 24, 2017
European Hematology Association: Bleeding or Clotting in Elderly Patients with Cancer-Associated Venous Thromboembolism: Which is Worse?